BOSTON, Jan. 08, 2026 -- Aktis Oncology, Inc. (“Aktis”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed...
A drug that could raise IQ - Balance Therapeutics raises $18M, conducting Down Syndrome trials
MedCity News, March 19, 2015 - Stanford spinout Balance Therapeutics just raised $18 million for its therapy that could raise the IQ of people with intellectual disability. It’s using a small molecule drug that has been around for decades – GABA-A antagonists – but rationalizes the approach by delving deeper into the molecular underpinnings of what causes diseases like Down Syndrome and dementia.
And it could improve the IQ of a person with Down Syndrome 10 to 20 percent.
